BIND Therapeutics Reports Fourth Quarter and Full Year 2015 Financial Results and Announces Shift in Research and Discovery Strategy to Focus on Developing Innovative Medicines Based on ACCURINS® Platform

BIND Therapeutics Reports Fourth Quarter and Full Year 2015 Financial Results and Announces Shift in Research and Discovery Strategy to Focus on Developing Innovative Medicines Based on ACCURINS® Platform

March 15, 2016

CAMBRIDGE, Mass.--(BUSINESS WIRE)--BIND Therapeutics, Inc. (NASDAQ: BIND), a biotechnology company developing targeted and programmable therapeutics called ACCURINS®, today reported financial results for the fourth quarter and full year 2015. Additionally, the Company announced a shift in its research and discovery strategy to focus on the development of innovative medicines, primarily in cancer.

Publication in Science Further Validates Importance of Gene Control Research in Yielding New Insights into Diagnosing and Treating Cancer

Publication in Science Further Validates Importance of Gene Control Research in Yielding New Insights into Diagnosing and Treating Cancer

March 3, 2016

CAMBRIDGE, Mass., March 3, 2016 – Syros Pharmaceuticals announced today that research from its scientific co-founder Richard Young, Ph.D., reveals a new mechanism by which genetic alterations in non-coding regions of the DNA fuel cancer growth, providing further validation for Syros’ pioneering approach to discover and develop medicines that control the expression of genes with the aim of treating cancer and other serious diseases.

Acceleron Pharma Reports Fourth Quarter and Year Ended 2015 Financial and Operational Results and Recent Highlights

Acceleron Pharma Reports Fourth Quarter and Year Ended 2015 Financial and Operational Results and Recent Highlights

February 25, 2016

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic candidates that regulate cellular growth and repair, today provided a corporate update and reported financial results for the fourth quarter and year ended December 31, 2015.

Seres Therapeutics Reports Fourth Quarter and Full Year 2015 Financial Results and Provides Business Update

Seres Therapeutics Reports Fourth Quarter and Full Year 2015 Financial Results and Provides Business Update

February 25, 2016

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 25, 2016-- Seres Therapeutics Inc. (NASDAQ: MCRB), a leading microbiome therapeutics platform company, today reported financial results and provided a business update for the fourth quarter and full year ended December 31, 2015.

The company highlighted the progress it made in advancing its commercial strategy and expanding its pipeline into new indications.

Transmedics Announces the World's First Human Liver Transplantation Using the Organ Care System (OCS™) Liver Technology and the Initiation of the OCS™ Liver Protect U.S. Pivotal Trial

Transmedics Announces the World's First Human Liver Transplantation Using the Organ Care System (OCS™) Liver Technology and the Initiation of the OCS™ Liver Protect U.S. Pivotal Trial

February 23, 2016

Andover, Mass., February 23, 2016 -- TransMedics, Inc., the global leader in portable ex-vivo warm perfusion of donor organs for transplantation, announces the world's first human liver transplantation using the OCS™ Liver technology and the initiation of the OCS™ Liver PROTECT Pivotal Trial.

The transplant procedure was performed by Dr. James F. Markmann, Chief of Transplant Surgery at Massachusetts General Hospital. Dr. Markmann is a principal investigator and Chairman of the Steering Committee for the PROTECT Trial.

Oasys Water Continues Expansion of Global Operations to Deliver Treatment Innovation to the Middle East

Oasys Water Continues Expansion of Global Operations to Deliver Treatment Innovation to the Middle East

February 23, 2016

Boston – February 23, 2016 – Oasys Water, the world leader committed to developing innovative Forward Osmosis (FO)-based solutions for transforming complex industrial wastewater streams into valuable freshwater resources, today announced that it has opened an office in Dubai to support business opportunities in the Middle East and Gulf Cooperation Council (GCC) region.

Pronutria Biosciences Announces $42.5 Million Equity Investment from Nestlé Health Science

Pronutria Biosciences Announces $42.5 Million Equity Investment from Nestlé Health Science

February 23, 2016

CAMBRIDGE MA – February 23, 2016 / BUSINESS WIRE / – Pronutria Biosciences Inc., a biotechnology company pioneering first-in-class medicines for serious conditions linked to amino acid imbalances, announced today that it has completed a $42.5 million investment by Nestlé Health Science.

The proceeds from this financing will help to fund the ongoing rapid transformation of the company from a unique and revolutionary platform to late stage clinical candidates in several disease indications.

Agios Reports Fourth Quarter and Full Year 2015 Financial Results and Highlights Key 2016 Milestones

Agios Reports Fourth Quarter and Full Year 2015 Financial Results and Highlights Key 2016 Milestones

February 18, 2016

CAMBRIDGE, Mass., Feb. 18, 2016 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today reported business highlights and financial results for the fourth quarter and year ended December 31, 2015. In addition, Agios highlighted select corporate milestones for its preclinical and clinical development programs.

T2 Biosystems Reports 2015 Fourth Quarter, Full Year Results

T2 Biosystems Reports 2015 Fourth Quarter, Full Year Results

February 16, 2016

LEXINGTON, Mass., Feb. 16, 2016 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) today reported operating highlights and financial results for the fourth quarter and year ended December 31, 2015. Recent operational highlights included:

During the fourth quarter, the Company received commitments for the adoption of T2Candida® and the T2Dx® with 11 new hospitals in the United States, including two multi-facility hospital systems of 22 and 14 hospitals, respectively. This brought the total number of commitments to 30 as of December 31, 2015.

BIND Therapeutics and Synergy Pharmaceuticals Announce Collaboration to Develop ACCURINS® with Proprietary Uroguanylin Analogs for Targeting Gastrointestinal Receptors on Tumors

BIND Therapeutics and Synergy Pharmaceuticals Announce Collaboration to Develop ACCURINS® with Proprietary Uroguanylin Analogs for Targeting Gastrointestinal Receptors on Tumors

February 16, 2016

CAMBRIDGE, Mass. & NEW YORK--(BUSINESS WIRE)-- BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine company developing targeted and programmable therapeutics called ACCURINS®, and Synergy Pharmaceuticals Inc.